AVIDITY BIOSCIENCES

avidity-biosciences-logo

Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more eff... ectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types.

#SimilarOrganizations #People #Financial #Event #Website #More

AVIDITY BIOSCIENCES

Social Links:

Industry:
Biotechnology Health Care Life Science Pharmaceutical Therapeutics

Founded:
2013-01-01

Address:
San Diego, California, United States

Country:
United States

Website Url:
http://www.aviditybiosciences.com

Total Employee:
251+

Status:
Active

Contact:
858-401-7900

Email Addresses:
info@aviditybio.com

Total Funding:
1.21 B USD


Similar Organizations

abzena-logo

Abzena

Abzena provides complementary services to organizations involved in the development of bio-pharmaceuticals.

arcellx-logo

Arcellx

Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.

aura-biosciences-logo

Aura Biosciences

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.

nutcracker-therapeutics-logo

Nutcracker Therapeutics

Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.

pyxis-biologix-logo

Pyxis Biologix

Pyxis Biologix is a biotech company that develops topical pharmaceutical peptide serum for skin disorders.

syros-pharmaceuticals-logo

Syros Pharmaceuticals

Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.

vigil-neuroscience-logo

Vigil Neuroscience

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.


Current Advisors List

troy-wilson_image

Troy Wilson Chairman Of The Board Of Directors @ Avidity Biosciences
Board_member
2012-01-01

jean-kim_image

Jean Kim Board Member @ Avidity Biosciences
Board_member
2021-01-01

arthur-levin_image

Arthur Levin Board of Directors @ Avidity Biosciences
Board_member
2023-02-01

Current Employees Featured

frank-mccormick_image

Frank McCormick
Frank McCormick Co-Founder @ Avidity Biosciences
Co-Founder
2012-12-01

steve-hughes_image

Steve Hughes
Steve Hughes Chief Medical Officer @ Avidity Biosciences
Chief Medical Officer
2022-02-01

mark-e-davis_image

Mark E. Davis
Mark E. Davis Founder @ Avidity Biosciences
Founder

sarah-boyce_image

Sarah Boyce
Sarah Boyce President & CEO @ Avidity Biosciences
President & CEO
2019-10-01

andrew-geall_image

Andrew Geall
Andrew Geall Vice President of Formulations and Chemistry @ Avidity Biosciences
Vice President of Formulations and Chemistry
2015-01-01

michael-maclean_image

Michael MacLean
Michael MacLean Chief Financial Officer @ Avidity Biosciences
Chief Financial Officer
2020-05-01

Founder


frank-mccormick_image

Frank McCormick

mark-e-davis_image

Mark E. Davis

p-kent-hawryluk_image

P. Kent Hawryluk

troy-wilson_image

Troy Wilson

Stock Details


Company's stock symbol is NASDAQ:RNA

Investors List

farallon-capital-management_image

Farallon Capital Management

Farallon Capital Management investment in Post-IPO Equity - Avidity Biosciences

janus-henderson-investors_image

Janus Henderson Investors

Janus Henderson Investors investment in Post-IPO Equity - Avidity Biosciences

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Post-IPO Equity - Avidity Biosciences

wellington-management_image

Wellington Management

Wellington Management investment in Post-IPO Equity - Avidity Biosciences

casdin-capital_image

Casdin Capital

Casdin Capital investment in Post-IPO Equity - Avidity Biosciences

boxer-capital_image

Boxer Capital

Boxer Capital investment in Post-IPO Equity - Avidity Biosciences

adage-capital-management_image

Adage Capital Management

Adage Capital Management investment in Post-IPO Equity - Avidity Biosciences

rtw-investments-llc_image

RTW Investments

RTW Investments investment in Post-IPO Equity - Avidity Biosciences

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series C - Avidity Biosciences

takeda-ventures_image

Takeda Ventures

Takeda Ventures investment in Series C - Avidity Biosciences

Official Site Inspections

http://www.aviditybiosciences.com Semrush global rank: 1.47 M Semrush visits lastest month: 16.82 K

  • Host name: 23.185.0.3
  • IP address: 23.185.0.3
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Avidity Biosciences"

Overview - Avidity Biosciences

Our Broad and Disruptive Platform We are delivering a new class of RNA therapeutics – Antibody Oligonucleotide Conjugates (AOCs™). AOCs are designed to combine the specificity of monoclonal antibodies with the …See details»

Collaborations and Partnerships - Avidity Biosciences

We continue to broaden the reach of AOCs with our advancing and expanding pipeline as we transform to become a global commercial organization. In addition to our own internal research programs, we continue to explore the full …See details»

Avidity Biosciences Plans First BLA Submission and Accelerates ...

Jan 8, 2025 successful product launches; Avidity's efforts to build a global commercial organization may be unsuccessful; unexpected adverse side effects to, or inadequate efficacy …See details»

Avidity Biosciences, Inc. | LinkedIn

Avidity Biosciences, Inc. | 25,051 followers on LinkedIn. DELIVERING ON OUR VISION Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re ...See details»

January 2021 Avidity Corporate Presentation

BUILDING an extraordinary biotech organization to bring our AOC therapies to patients. ESTABLISHING the right teams and growing together in service of patients and their families. …See details»

Avidity Biosciences - Crunchbase Company Profile

Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases.See details»

Avidity Biosciences, Inc. - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Avidity Biosciences, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»

Avidity Biosciences - BioSpace

We are dedicated to employing and retaining an inclusive workforce at all levels of the organization to ensure that different backgrounds and perspectives are being heard and integrated. Through our BeAVID values – Agile, Visionary, …See details»

Avidity Biosciences Inc Company Profile - Overview - GlobalData

Website www.aviditybiosciences.com Telephone 1 858 4017900. No of Employees 391. Industry Pharmaceuticals and Healthcare. Ticker Symbol & Exchange RNA (NASD) Revenue (2023) …See details»

Avidity Biosciences - Craft

Oct 29, 2024 Avidity Biosciences is a biotech company developing oligonucleotide-based therapies called antibody oligonucleotide conjugates (AOC). The company utilizes its AOC …See details»

About - Avidity Biosciences

Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop …See details»

Avidity Biosciences - 2025 Company Profile - Tracxn

May 2, 2025 Avidity Biosciences - Develops antibody-siRNA complexes to treat cancer. Public Company. Raised a total funding of $143M over 7 rounds from 21 investors. Founded by Troy …See details»

Avidity Biosciences - Work in biotech

Avidity Biosciences is developing a new class of RNA therapies to treat rare genetic diseases. Avidity has developed an innovative pipeline built upon their Antibody Oligonucleotide …See details»

Avidity Biosciences - VentureRadar

"Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines - Antibody-siRNA Conjugates (ASC) - which combine the strengths of monoclonal …See details»

Avidity Biosciences - F6S

DELIVERING ON OUR VISION Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform …See details»

Avidity Biosciences to Participate in Upcoming Investor Conference

3 days ago Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:00 p.m. About Avidity Avidity Biosciences, Inc.' s mission is to profoundly improve …See details»

What is Avidity Biosciences? Company Culture, Mission, Values

Glassdoor gives you an inside look at what it's like to work at Avidity Biosciences, including salaries, reviews, office photos and more. This is the Avidity Biosciences company profile.See details»

Avidity Biosciences - Overview, News & Similar companies

Avidity Biosciences contact info: Phone number: (858) 401-7900 Website: www.aviditybiosciences.com What does Avidity Biosciences do? Avidity Biosciences, Inc.'s …See details»

Avidity Biosciences to Participate in Upcoming Investor Conference

3 days ago (PRNewsfoto/Avidity Biosciences, Inc.) Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:00 p.m. PT / 6:00 p.m. ET. Live webcast of the …See details»

Overview - Avidity Biosciences

Utilizing our proprietary Antibody Oligonucleotide Conjugates (AOCs™) platform, Avidity was the first company to demonstrate the successful targeted delivery of RNA to muscle. This …See details»

linkstock.net © 2022. All rights reserved